Interferon (IFN)-beta induces S-phase slowing and apoptosis in human papilloma virus (HPV)-positive cervical carcinoma cell line ME-180. Here, we show that apoptosis is a consequence of the S-phase lengthening imposed by IFN-beta, demonstrating the functional correlation between S-phase alteration and apoptosis induction. In ME-180 cells, where p53 function is inhibited by HPV E6 oncoprotein, IFN-beta effects on cell cycle and apoptosis occur independently of p53. The apoptosis due to IFN-beta is mediated by the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in a manner dependent on the S-phase deregulation. IFN-beta appears to increase TRAIL expression both directly at the mRNA level and indirectly by augmenting surface pr...
Viruses have developed sophisticated strategies to evade host defenses and facilitate the production...
Abstract Background Interferon-α (IFN-α) exerts an anti-tumor effect at least through induction of a...
International audienceThe combination of neoadjuvant chemotherapy, radiochemotherapy, and maintenanc...
Interferon (IFN)-beta induces S-phase slowing and apoptosis in human papilloma virus (HPV)-positive ...
Interferon-alfa induces S-phase slowing and cell death in HPV-positive human cervical carcinoma cell...
Interferon (IFN)-alfa induces a significant antiproliferative action in cervical carcinoma cells, ex...
We demonstrated the induction of cell death in a hepatoma cell line by IFN-gamma and its possible me...
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine produced and secreted ...
The powerful inducer of apoptosis Apo2L/TNF-related apoptosis-inducing ligand (TRAIL) has generated ...
The powerful inducer of apoptosis Apo2L/TNF-related apoptosis-inducing ligand (TRAIL) has generated ...
TNF-related apoptosis-inducing ligand (TRAIL, also called Apo2L), a novel member of TNF superfamily,...
[[abstract]]Various human colon cancer cell lines tested in vitro differed significantly in suscepti...
Type I Interferon (IFN) and all-trans retinoic acid (RA) inhibit cell proliferation of squamous carc...
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising molecule for an...
Type I Interferon (IFN) and all-trans retinoic acid (RA) inhibit cell proliferation of squamous carc...
Viruses have developed sophisticated strategies to evade host defenses and facilitate the production...
Abstract Background Interferon-α (IFN-α) exerts an anti-tumor effect at least through induction of a...
International audienceThe combination of neoadjuvant chemotherapy, radiochemotherapy, and maintenanc...
Interferon (IFN)-beta induces S-phase slowing and apoptosis in human papilloma virus (HPV)-positive ...
Interferon-alfa induces S-phase slowing and cell death in HPV-positive human cervical carcinoma cell...
Interferon (IFN)-alfa induces a significant antiproliferative action in cervical carcinoma cells, ex...
We demonstrated the induction of cell death in a hepatoma cell line by IFN-gamma and its possible me...
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine produced and secreted ...
The powerful inducer of apoptosis Apo2L/TNF-related apoptosis-inducing ligand (TRAIL) has generated ...
The powerful inducer of apoptosis Apo2L/TNF-related apoptosis-inducing ligand (TRAIL) has generated ...
TNF-related apoptosis-inducing ligand (TRAIL, also called Apo2L), a novel member of TNF superfamily,...
[[abstract]]Various human colon cancer cell lines tested in vitro differed significantly in suscepti...
Type I Interferon (IFN) and all-trans retinoic acid (RA) inhibit cell proliferation of squamous carc...
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising molecule for an...
Type I Interferon (IFN) and all-trans retinoic acid (RA) inhibit cell proliferation of squamous carc...
Viruses have developed sophisticated strategies to evade host defenses and facilitate the production...
Abstract Background Interferon-α (IFN-α) exerts an anti-tumor effect at least through induction of a...
International audienceThe combination of neoadjuvant chemotherapy, radiochemotherapy, and maintenanc...